HER2 低表達乳癌 - 研發管線分析：2023 年

HER2-Low Breast Cancer- Pipeline Analytics 2023

出版日期: 2023年09月22日 | 出版商:

Mellalta Meets LLP | 英文 180 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

目前，超過50%的乳癌被定義為“人類表皮生長因子受體2（HER2）-低乳癌（BC）”，HER2免疫組織化學（IHC）評分為+1或+2，螢光原位雜交（FISH）檢測結果為陰性。隨著越來越多的公司尋求在 HER2 低表達腫瘤中開發和商業化治療性 ADC，不斷變化的治療模式正在為市場創造新的機會。

目前，HER2 低乳癌產品線中有超過 33 個候選藥物正在臨床和臨床前研究中進行評估。市場的主要參與者包括江蘇恆瑞醫藥、Duuality Biologics、煙台榮昌製藥、吉利德科學、阿斯特捷利康/第一三共等，它們擁有強大的 HER2 低表達乳癌候選藥物臨床管線。

本報告調查了全球 HER2-low 乳癌市場，涵蓋了按開發階段劃分的管道產品分析、按階段劃分的競爭格局、公司、治療領域和適應症。它還提供當前的市場機會、市場驅動因素/挑戰等。

The “HER2-Low Breast Cancer -Pipeline Analytics -2023” report published by Mellalta Meets covers the HER2-Low Breast Cancer Therapies market opportunity providing Key Competitive Analysis, 30+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports cover pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. HER2-Low Metastatic Breast Cancer reports add value in terms of providing the description of clinical-stage products with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.

The introduction of HER2-low breast cancer represents a significant shift in the understanding and treatment of breast cancer. More than 50% of breast cancers are currently defined as "Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC)", with HER2 immunohistochemistry (IHC) scores of +1 or +2 with a negative fluorescence in situ hybridization (FISH) test. The changing treatment landscape has created new opportunities in the market for more companies to develop and commercialize the use of therapeutic ADCs in HER2-low tumors.

In this report, Mellalta Meets provides an in-depth analysis of the HER2-Low Breast Cancer Pipeline covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 33+ candidates in the HER2-Low Breast Cancer Pipeline under evaluation in clinical and preclinical studies. The major key players operating in the market are Jiangsu HengRui Medicine, Duality Biologics, Yantai Rongchang Pharmaceutical, Gilead Sciences, AstraZeneca/Daiichi Sankyo and many more which have robust clinical pipeline of HER2-Low Breast Cancer candidates.

As per analysis, the development pipeline is full of different ADCs and combination approaches which can help in addressing this new subtype of Breast cancer.

Mellalta's HER2-Low Breast Cancer Pipeline Report- Market Summary

Report Attributes	Details
Key Late Stage Market Players:	Jiangsu HengRui Medicine; Duality Biologics; Yantai Rongchang Pharmaceutical; Gilead Sciences; AstraZeneca/Daiichi Sankyo.
Lead Assets:	Phase 3 (10+); Phase 2 (10+); Phase 1 (5+); Preclinical (3+); Discovery stages.

Mellalta's HER2-Low Breast Cancer Pipeline Report - Key Highlights

There are ~10 products in the Phase 3 stage of development, representing ~35% of the total share of the developing HER2-Low Breast Cancer Therapeutics landscape.

The pipeline of HER2-Low Breast Cancer therapies is dominated by the Phase III (10+) assets; Phase II (10+); Phase I (5+) and Preclinical (3+) and Discovery assets.

To be continued…

Report Coverage:

Indication Prioritization: HER2-Low Breast Cancer market potential based on Indications

Business Transactions & Strategies: Key collaborations and deal values

HER2-Low Breast Cancer Pipeline Development: Product Profiles, Clinical Trials & Results

HER2-Low Breast Cancer Acquisition Targets

HER2-Low Breast Cancer Competitive Intelligence

Recent and upcoming events

Table of Content

1. REPORT OVERVIEW

2. OVERVIEW

2.1. HER2-Low Breast Cancer - Overview
2.2. Diagnostic tools for HER2-Low Breast Cancer
2.3. AI-based HER2-low IHC scoring in breast cancer
2.4. Diagnostic tools for HER2-Low Breast Cancer detection: Limitations
2.5. Current Challenges with HER2-Low Breast Cancer

3. HER2-LOW BREAST CANCER PIPELINE ANALYSIS

3.1. Overview
3.2. Assets by Indication/Phase
3.3. Pipeline Products by Stage of Development
3.4. HER2-Low Breast Cancer Competitive Landscape
3.5. Pipeline Products by Company and Phases
3.6. HER2-Low Breast Cancer Clinical & Regulatory Timelines

4. HER2-LOW BREAST CANCER ACQUISITIONS, LICENSING AND COLLABORATION DEALS

4.1. HER2-Low Breast Cancer Acquisitions, Licensing and Deal values
4.2. HER2-Low Breast Cancer Acquisitions, Licensing by Transaction type and total amount size by Phases
4.3. Promising Technologies Under development

5. HER2-Low Breast Cancer PIPELINE LANDSCAPE

5.1. Profile at Glance
5.2. Late-Stage Assets Comparisons At-a-glance
5.3. HER2-Low Breast Cancer Pipeline Drug Profiles
- 5.3.1. Phase III
  - 5.3.1.1. Duality Biologics: DB-1303
    - 5.3.1.1.1. Product Profile & Description
    - 5.3.1.1.2. Collaborations
    - 5.3.1.1.3. Other Developments
    - 5.3.1.1.4. Clinical Trials
  - 5.3.1.2. Jiangsu HengRui Medicine: Trastuzumab rezetecan
    - 5.3.1.2.1. Product Profile & Description
    - 5.3.1.2.2. Collaborations
    - 5.3.1.2.3. Other Developments
    - 5.3.1.2.4. Clinical Trials
  - 5.3.1.3. RemeGen/Seagen: Disitamab vedotin
    - 5.3.1.3.1. Product Profile & Description
    - 5.3.1.3.2. Collaborations
    - 5.3.1.3.3. Other Developments
    - 5.3.1.3.4. Clinical Trials
    - 5.3.1.3.5. Others…
  - 5.3.1.4. Phase II
    - 5.3.1.4.1. Miracogen: MRG002
      - 5.3.1.4.1.1. Product Profile & Description
      - 5.3.1.4.1.2. Collaborations
      - 5.3.1.4.1.3. Other Developments
      - 5.3.1.4.1.4. Clinical Trials
    - 5.3.1.4.2. Merus: MCLA-128
      - 5.3.1.4.2.1. Product Profile & Description
      - 5.3.1.4.2.2. Collaborations
      - 5.3.1.4.2.3. Other Developments
      - 5.3.1.4.2.4. Clinical Trials
      - 5.3.1.4.2.5. Others…
    - 5.3.1.4.3. Phase I
      - 5.3.1.4.3.1. Sichuan Baili Pharmaceutical/SystImmune: BL-M07D1
      - 5.3.1.4.3.2. Product Profile & Description
      - 5.3.1.4.3.3. Collaborations
      - 5.3.1.4.3.4. Other Developments
      - 5.3.1.4.3.5. Clinical Trials
    - 5.3.1.4.4. HighField Biopharmaceuticals Corporation: HF158K1
      - 5.3.1.4.4.1. Product Profile & Description
      - 5.3.1.4.4.2. Collaborations
      - 5.3.1.4.4.3. Other Developments
      - 5.3.1.4.4.4. Clinical Trials
      - 5.3.1.4.4.5. Others…